The Center
Multiple Sclerosis Center Dresden
Patient Information
Contact MSC
Physicians & Nurses
Study Team
Neuropsychology
Mobility Center
The Mobility Center
Walking Assessment
Jump Assessment
DIERS
EMIQ
Projects
Neuroimmunological Laboratory
The NIL
Neurofilament light chain
Autonomic & Neuroendocrinological Functional Laboratory
The ANF
ANF Assessment
MS Living Lab
Management & Science
Team Management & Science
Projects
eHealth & Analytics
MSDS 3D
MSDS Clinic & Practice
MS-HRS
MTRS
Multiple Sclerosis Management
Aktuelles
Neuigkeiten
Publikationen
Veranstaltungen
Adventssymposium
Multiple Sklerose 360°
Welt-MS-Tag 2021
Doktorarbeiten
Jobs
Kontakt
Podcasts & Newsletter
Newsletter
Patienten-Podcast
Ärzte-Podcast
Neurovision
Studien
Interventionelle Studien
B-SHUTTLE
Nicht-interventionelle Studien
MS PATHS
Konectom
Sprachanalyse
English (UK)
Deutsch
English (UK)
Gaining first insights on secondary progressive multiple sclerosis patients treated with siponimod in clinical routine: Protocol of the noninterventional study Amasia
MS Treatments
Jahr
Publikationsjahr
2020
Autoren
Autorenliste der Publikation
Ziemssen T, Hoffmann O, Klotz L, Schreiber H, Weber MS, Rauser B.
Verlag
Publisher-Information
JMIR Res Prot 2020;9(7).
Link
Zur Publikation (externer Server)
https://doi.org/10.2196/19598
Tags
Forschungsthemen
Multiple Sklerose
MS Behandlung
Treatments
2020
MS brain health quality standards: a survey on the reality in clinical practice in Germany
Multiple Sclerosis
Jahr
2024
Best supportive care for patients with primary progressive multiple sclerosis (PPMS) in Germany prior to ocrelizumab treatment: Final results from the RETRO PPMS study
MS Treatments
Jahr
2024
Harmonized Data Quality Indicators Maintain Data Quality in Long-Term Safety Studies Using Multiple Sclerosis Registries/Data Sources: Experience from the CLARION Study
Multiple Sclerosis
Jahr
2024
Eculizumab Use in Neuromyelitis Optica Spectrum Disorders
MS Treatments
Jahr
2024
Long-term effects of siponimod on cardiovascular and autonomic nervous system in secondary progressive multiple sclerosis
ANF
Jahr
2024